Australian Health Experts Back Continued Access To Puberty Blockers Under Clinical Guidance


Australia’s leading medical research body has released new advice supporting the carefully assessed use of puberty blockers for some transgender and gender-diverse young people, marking a significant development in the ongoing debate over access to gender-affirming healthcare.

The National Health and Medical Research Council (NHMRC) released its interim clinical advice on Monday 16 November 2026, concluding that puberty blockers can be considered as a treatment option for certain transgender and gender-diverse people under 18.

The advice follows a review of available research and input from clinicians, researchers and people with lived experience.

Rather than recommending the treatment for every young person, the council emphasises individual assessment, informed decision-making and ongoing medical monitoring.

The announcement comes as access to puberty blockers remains restricted in parts of Australia, while New Zealand recently experienced its own significant legal development concerning the medication.

What Does Australia’s New Advice Say?

The NHMRC’s proposed advice recommends that puberty blockers remain a clinical option for some young people experiencing gender incongruence.

Gender incongruence describes a difference between someone’s experienced gender and the sex recorded for them at birth. Some young people also experience distress associated with that difference, known as gender dysphoria.

Puberty blockers, also called puberty suppressants, are medications that suppress the hormones responsible for aspects of pubertal development.

They have long been used in paediatric healthcare, including for children experiencing unusually early puberty.

For transgender and gender-diverse young people, they may be considered to pause some physical changes associated with puberty while the young person receives appropriate clinical support.

However, the NHMRC stresses that treatment is not suitable or necessary for everyone.

Its advice calls for decisions to involve a comprehensive assessment, appropriate information for young people and their parents or carers, and input from a multidisciplinary healthcare team tailored to individual needs.

Regular monitoring is also recommended throughout treatment.

What Does The Medical Evidence Show?

The council’s interim advice is based on a systematic review of the available evidence.

According to ABC News, the review examined 15 non-randomised studies, many involving relatively short follow-up periods.

The NHMRC concluded that the overall certainty of the evidence remains low.

The available research suggests possible benefits for some young people’s psychosocial wellbeing, but the studies do not establish the size or certainty of those benefits conclusively.

The council also identified important gaps in evidence about longer-term outcomes, including fertility and aspects of bone health.

Although serious adverse events appeared uncommon in the studies reviewed, the NHMRC emphasised the importance of monitoring for possible complications.

These uncertainties form part of the reason its recommendation is conditional rather than a blanket endorsement of treatment.

In clinical guideline development, a conditional recommendation means that different decisions may be appropriate depending on the individual patient, their circumstances and their preferences.

The council’s position is that puberty blockers may be considered following careful assessment and shared decision-making, not that they should automatically be prescribed.

Queensland And Northern Territory Restrictions Remain

The advice could have particular implications for Australian states and territories where access to puberty blockers has been restricted.

Queensland introduced restrictions on new prescriptions through its public gender services in 2025, while the Northern Territory also limited access for people under 18.

The new national advice may increase scrutiny of those policies.

However, the NHMRC’s recommendations are advisory and do not automatically override state or territory decisions.

ABC News reports that Queensland intends to maintain its current restrictions while awaiting further research, including the outcome of a proposed British clinical trial.

Australian Health Minister Mark Butler said the advice was developed using systematic evidence review and clinical expertise.

He emphasised that decisions about puberty blockers should be based on individual needs rather than a single approach applying to every patient.

The broader national guidelines covering gender-affirming healthcare for young people remain under development, with public consultation expected in early 2028.

What Is Happening With Puberty Blockers In New Zealand?

The Australian announcement follows a major development concerning gender-affirming healthcare in Aotearoa.

On 21 October 2026, New Zealand’s High Court set aside Government regulations restricting new prescriptions of puberty blockers for young people experiencing gender dysphoria or gender incongruence.

The regulations had been introduced in November 2025 and came into force the following month.

However, their enforcement had been suspended while a judicial review was considered.

Following the High Court’s decision, the Ministry of Health confirmed that clinicians could prescribe puberty blockers for young people with gender dysphoria or gender incongruence.

The Ministry also emphasised that healthcare providers should take a holistic approach, including comprehensive assessment and consideration of medical, mental health and social support.

The decision does not mean puberty blockers are automatically prescribed to everyone who requests them.

Treatment still involves clinical assessment and appropriate medical oversight.

The developments in Australia and New Zealand highlight how health authorities are responding to the available research while considering the needs of transgender and gender-diverse young people.

Why Access To Appropriate Healthcare Matters

For transgender, non-binary and takatāpui young people and their whānau, decisions about healthcare can have a significant impact on wellbeing.

Access to suitable services may involve specialist assessments, ongoing appointments and support for families navigating complex decisions.

LGBTQ+ health advocates have consistently emphasised the importance of respectful, individualised care that recognises the diversity of young people’s experiences.

The NHMRC’s interim position acknowledges that not all young people need the same intervention or will make the same treatment decisions.

It also recognises the need for further research into the benefits, risks and longer-term outcomes of puberty suppression.

For families and healthcare professionals, the immediate significance is that Australia’s national medical research body has recommended retaining puberty blockers as a possible treatment under defined clinical circumstances.

Australians Invited To Have Their Say

The NHMRC has opened a nine-week public consultation on the proposed advice.

The consultation invites feedback from young people, families, clinicians, researchers, professional organisations and others with relevant knowledge or experience.

Submissions can address the medical evidence, proposed recommendations, clinical practice statements and how the advice might be implemented.

Public consultation closes at 1pm Australian Eastern Daylight Time on Monday 18 January 2027.

The feedback will inform the development of Australia’s broader national clinical guidelines.

While questions about the evidence and long-term outcomes remain, the interim advice establishes that puberty blockers should remain a treatment option for some transgender and gender-diverse young people following careful, individualised assessment.

Share the Post:

Latest Posts